Compare REGN & EA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | EA |
|---|---|---|
| Founded | 1988 | 1982 |
| Country | United States | United States |
| Employees | 15207 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.3B | 51.1B |
| IPO Year | 1991 | N/A |
| Metric | REGN | EA |
|---|---|---|
| Price | $745.77 | $204.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 22 |
| Target Price | ★ $799.33 | $185.81 |
| AVG Volume (30 Days) | 818.5K | ★ 1.6M |
| Earning Date | 01-30-2026 | 02-03-2026 |
| Dividend Yield | ★ 0.47% | 0.37% |
| EPS Growth | ★ 2.88 | N/A |
| EPS | ★ 41.59 | 3.45 |
| Revenue | ★ $14,247,800,000.00 | $7,288,000,000.00 |
| Revenue This Year | $2.08 | $10.73 |
| Revenue Next Year | $6.82 | $3.61 |
| P/E Ratio | ★ $18.13 | $59.17 |
| Revenue Growth | ★ 2.89 | N/A |
| 52 Week Low | $476.49 | $115.21 |
| 52 Week High | $821.11 | $204.89 |
| Indicator | REGN | EA |
|---|---|---|
| Relative Strength Index (RSI) | 45.12 | 59.30 |
| Support Level | $743.94 | $204.03 |
| Resistance Level | $766.64 | $204.60 |
| Average True Range (ATR) | 19.11 | 0.34 |
| MACD | -6.71 | -0.15 |
| Stochastic Oscillator | 4.91 | 29.83 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Electronic Arts is one of the largest global developers and publishers of video games. Its most important franchises are the Madden NFL and FC soccer games, which it releases annually. In 2024, it also relaunched its American college football game. Other major franchises include Apex Legends, Battlefield, and The Sims. Typically, about three quarters of the firm's sales are from in-game spending, with the remainder coming from initial game sales.